- Bankruptcies Jump, Hitting Highest Level in Four Years
- AIG, Ex-CEO Greenberg Reach Pact to Settle Disputes
- Bank of America CEO Search May Extend Into 2010
- Steepest Black Friday Discounts, Revealed
- 'Cancer of Fraud' Permeates Health Care System: Critics
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Judge Erases Couple's $525,000 Mortgage Payment
- Where Do Pardoned Turkeys Go?
- For Many in US, It Will Be a Scaled-Down Holiday Season
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
MOST SHARED
- The Executive Job Search
- S&P Stocks Trading at New 52-Week Highs
- Where Do Pardoned Turkeys Go?
- Judge Erases Couple's $525,000 Mortgage Payment
- Salvation Army's Kettles Now Credit Card-Ready
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- Topless Business Is Taking Off
- US Plans to Reduce Emissions By 17% Within Next Ten Years
- Black Friday: Can Banks Tap the Frenzy, Too?
Text Size 
DUBLIN, Nov 7 (Reuters) - Ireland's Elan and U.S. drugmaker Biogen Idec have amended the label of their multiple sclerosis drug Tysabri to reflect the increased risk of contracting a potentially deadly brain infection, Elan said in a statement on Saturday. Last month European regulators began a review of the drug following reports of 23 cases of progressive multifocal leukoencephalopathy, or PML. The label changes specified that the occurrence of PML in patients treated for 24 to 36 months is generally similar to the 1-in-1,000 rate seen in clinical trials, Elan said. Tysabri was temporarily withdrawn from the market in 2005 after being linked with PML. It was reintroduced in July 2006 with stricter safety warnings. Tysabri is considered the most important driver of growth for Elan and Biogen and shares in both companies fell sharply after the most recent PML cases were reported last month. (Reporting by Padraic Halpin; editing by Chris Pizzey) Keywords: ELAN/ (padraic.halpin@reuters.com; Reuters Messaging: padraic.halpin.reuters.com@reuters.net; +353 1 500 1504) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
- How can you get out of debt and back on the road to recovery? Follow these ten steps.
Data is a real-time snapshot *Data is delayed at least 15 minutes